Guangxi Wuzhou Zhongheng Group (600252) announced on the evening of January 1 that, according to the announcement of the proposed selection results for centralized procurement by the national Chinese Patent Medicine procurement alliance released by the National Chinese Patent Medicine Joint Procurement Office on December 30, 2024, on the Hubei medical insurance service platform, the company's holding subsidiary Wuzhou Pharmaceutical's product, injectable thrombin (freeze-dried), is expected to win the bid for this centralized procurement.
中恒集团:控股子公司产品拟中选全国中成药采购联盟集采
Guangxi Wuzhou Zhongheng Group: The products of its holding subsidiary are expected to be selected for the national Chinese Patent Medicine procurement alliance.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.